Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein
- PMID: 15308697
- PMCID: PMC506966
- DOI: 10.1128/JVI.78.17.9007-9015.2004
Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein
Abstract
The worldwide outbreak of severe acute respiratory syndrome (SARS) was shown to be associated with a novel coronavirus (CoV) now called SARS CoV. We report here the generation of SARS CoV S protein-pseudotyped murine leukemia virus (MLV) vector particles. The wild-type S protein pseudotyped MLV vectors, although at a low efficiency. Partial deletion of the cytoplasmic tail of S dramatically increased infectivity of pseudotypes, with titers only two- to threefold lower than those of pseudotypes generated in parallel with the vesicular stomatitis virus G protein. S-pseudotyped MLV particles were used to analyze viral tropism. MLV(SARS) pseudotypes and wild-type SARS CoV displayed similar cell types and tissue and host restrictions, indicating that the expression of a functional receptor is the major restraint in permissiveness to SARS CoV infection. Efficient gene transfer could be detected in Vero and CaCo2 cells, whereas the level of gene marking of 293T, HeLa, and HepG2 cells was only slightly above background levels. A cat cell line and a dog cell line were not susceptible. Interestingly, PK-15, a porcine kidney cell line, and primary porcine kidney cells were also highly permissive for SARS S pseudotypes and wild-type SARS CoV. This finding suggests that swine may be susceptible to SARS infection and may be a source for infection of humans. Taken together, these results indicate that MLV(SARS) pseudotypes are highly valuable for functional studies of viral tropism and entry and, in addition, can be a powerful tool for the development of therapeutic entry inhibitors without posing a biohazard to human beings.
Figures






Similar articles
-
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients.J Virol. 2004 Jun;78(12):6134-42. doi: 10.1128/JVI.78.12.6134-6142.2004. J Virol. 2004. PMID: 15163706 Free PMC article.
-
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9. doi: 10.1073/pnas.0403492101. Epub 2004 Jun 21. Proc Natl Acad Sci U S A. 2004. PMID: 15210961 Free PMC article.
-
Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.Emerg Infect Dis. 2005 Mar;11(3):411-6. doi: 10.3201/eid1103.040906. Emerg Infect Dis. 2005. PMID: 15757556 Free PMC article.
-
Vaccine design for severe acute respiratory syndrome coronavirus.Viral Immunol. 2005;18(2):327-32. doi: 10.1089/vim.2005.18.327. Viral Immunol. 2005. PMID: 16035944 Review.
-
SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission.Curr Opin Virol. 2011 Dec;1(6):624-34. doi: 10.1016/j.coviro.2011.10.012. Curr Opin Virol. 2011. PMID: 22180768 Free PMC article. Review.
Cited by
-
A novel pseudovirus-based mouse model of SARS-CoV-2 infection to test COVID-19 interventions.J Biomed Sci. 2021 Apr 30;28(1):34. doi: 10.1186/s12929-021-00729-3. J Biomed Sci. 2021. PMID: 33926459 Free PMC article.
-
Pseudotyped Viruses for Coronaviruses.Adv Exp Med Biol. 2023;1407:133-151. doi: 10.1007/978-981-99-0113-5_7. Adv Exp Med Biol. 2023. PMID: 36920695
-
SARS-CoV-2 spike engagement of ACE2 primes S2' site cleavage and fusion initiation.Proc Natl Acad Sci U S A. 2022 Jan 4;119(1):e2111199119. doi: 10.1073/pnas.2111199119. Proc Natl Acad Sci U S A. 2022. PMID: 34930824 Free PMC article.
-
In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential.Cell Rep. 2021 Oct 19;37(3):109838. doi: 10.1016/j.celrep.2021.109838. Epub 2021 Oct 5. Cell Rep. 2021. PMID: 34648735 Free PMC article.
-
Comparison of Four SARS-CoV-2 Neutralization Assays.Vaccines (Basel). 2020 Dec 28;9(1):13. doi: 10.3390/vaccines9010013. Vaccines (Basel). 2020. PMID: 33379160 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous